- Preliminary data for Celgene's Abraxane + durvalumab combo showed a benefit in progression-free survival (PFS) and disease control rate (DCR) (the percentage of patients who achieved complete response, partial response and stable disease), indicating that the combination of Abraxane and durvalumab is feasible with manageable toxicity. Abraxane monotherapy also presented promising preliminary efficacy and may be a potential second-line therapeutic option in patients with previously treated advanced stage NSCLC.
- Results from AstraZeneca and MedImmune’s phase III PACIFIC trial showed an improvement in PFS of more than 11 months in patients treated with Imfinzi (durvalumab) compared to placebo in patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy (CRT).
- New data on Ipsen and Exelixis' cabozantinib showed that the renal cell carcinoma drug had clinically meaningful and statistically significant efficacy results on the primary endpoint of PFS, compared to sunitinib, a current standard of care. Specifically, per the IRC review, cabozantinib demonstrated a 52 percent reduction in the rate of disease progression or death (HR = 0.48, 95% CI 0.31-0.74, two-sided P=0.0008). The median PFS for cabozantinib was 8.6 months versus 5.3 months for sunitinib.
- Bristol-Myers Squibb announced superior overall survival (OS) results from a phase III study (CheckMate -214) evaluating nivolumab plus ipilimumab versus sunitinib in patients with previously-untreated advanced or metastatic clear cell renal cell carcinoma; in an interim analysis of overall survival (OS), the median OS in a sub-group of patients had not yet been reached for the combination and was 26 months for sunitinib, a current standard of care. The combination also demonstrated an objective response rate – the number of patients who saw a complete or partial reduction in their tumours – of 42%, with 9.4% of patients achieving a complete response, where no detectable sign of cancer remained.
- Eisai has announced interim results from the advanced renal cell carcinoma cohort of Study 111 of Kisplyx (lenvatinib) in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab). The results demonstrate that the combination achieved a confirmed objective response rate (ORR) at week 24 of 63% (95% CI: 44 – 80), and disease control rate, a secondary endpoint, was 96%.
- Novartis announced results from a Phase III study of 870 patients with stage III BRAF V600E/K mutation-positive melanoma treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib). Findings from the COMBI-AD study, which met its primary endpoint, found a statistically significant 53% reduction in the risk of death or recurrence in patients treated with the BRAF and MEK inhibitor combination therapy versus placebo.
- Clovis Oncology announced the first presentation of a comprehensive dataset from its Phase 3 ARIEL3 study of its ovarian cancer drug Rubraca (rucaparib). The ARIEL3 study successfully achieved its primary endpoint and key secondary endpoint, demonstrating improved PFS in each of the three populations studied.
- Results from the phase 3 LATITUDE clinical trial showed that treatment with Janssen’s Zytiga (abiraterone acetate) plus prednisone, in combination with androgen deprivation therapy (ADT), demonstrated clinically meaningful and statistically significant improvements in a range of patient reported outcomes in patients with newly diagnosed, high-risk, metastatic hormone-sensitive prostate cancer (mHSPC), compared to ADT alone. The study findings indicated that the treatment significantly delayed time to progression of worst pain intensity, pain interference, worst fatigue and compared to ADT plus placebos. Findings also show a significant improvement in health-related quality of life (HRQoL), which includes several measures such as physical and emotional wellbeing, demonstrating a reduction in risk of HRQoL degradation.
ESMO roundup – 11 September
Latest jobs from #PharmaRoleView all
Associate Director - Global Healthcare Consulting
The Medical Consulting team is a global healthcare consulting division within VMLY&R HEALTH, part of...
Strategy Director - Healthcare Advertising
About the agency VMLY&R HEALTH is the fastest growing global healthcare agency, filled with smart,...
Omnichannel Account Director
This is a great opportunity to join this progressive healthcare medical communications agency. They are...
£55,000 - £65,000 yearly
Senior Medical Writer
Client-facing role and work closely and collaboratively with the project managers, and health economics, and...
Pharmacovigilance Project Lead
Title: Pharmacovigilance Project Lead Location: Remote/Hybrid (UK and EU positions available) Job Summary: The Pharmacovigilance...
Title: Pharmacovigilance Manager Location: Remote/Hybrid, UK Job Summary: The Pharmacovigilance Manager will be responsible for...
Senior Account Manager: Patient Advocacy
This is an exceptional opportunity for a passionate and talented Healthcare PR and Comms Senior...
£40,000 - £50,000 yearly
Digital Account Manager: Integrated Agency
This is one of London’s most popular and successful boutique medical communication and healthcare advertising...
£35,000 - £45,000 yearly
Associate Director – Healthcare PR
Ref 33623 A global PR consultancy needs an additional associate director for its thriving London...
£75,000 - £85,000 yearly
Account Manager – Medical Communications
Seriously impressive London-based medical communications agency is looking for the next superstar in their client...
Kingsway, London WC2B 6AA, UK
£35,000 - £55,000 yearly
Account Executive - Medical Communications - Hybrid / Berkshire
Account Executive wanted for a very exciting opportunity with a Leading Medical Communications agency.Full on...
Principal Medical Writer
Several exciting business wins for this medical communications agency means it is looking for a...
Southampton Buildings, London WC2A 1AN, UK
£50,000 - £70,000 yearly
What job are you looking for?
Download our apps
Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.